A monoclonal antibody and kit for breast cancer detection

By designing antigen epitope polypeptides and monoclonal antibodies against PMEPA1 protein, the problem of low success rate and insufficient specificity of monoclonal antibody screening in breast cancer detection is solved, and high specificity and sensitivity of breast cancer detection is achieved, simplifying the Inspection process.

CN115925866BActive Publication Date: 2024-11-22GUANGZHOU PINK RIBBON BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211405138.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2022-03-09
Filing Date
2022-11-10
Publication Date
2024-11-22
Estimated Expiration
2042-11-10

AI Technical Summary

Technical Problem

The prior art is difficult to effectively utilize specific markers in breast cancer detection, resulting in low success rate of monoclonal antibody screening, insufficient specificity and sensitivity, and pairing tests are required.

Method used

A polypeptide of antigenic epitope targeting PMEPA1 protein was designed and a monoclonal antibody specifically bound to the epitope was developed for breast cancer detection, simplifying the monoclonal antibody screening process and improving its specificity and sensitivity , suitable for ELISA and other immunologic testing methods.

Benefits of technology

High specificity and sensitivity detection of PMEPA1 protein is achieved, the monoclonal antibody screening process is simplified, the use of null antibodies is avoided, and it is suitable for breast cancer diagnosis and shows good test results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115925866B_ABST
    Figure CN115925866B_ABST
Patent Text Reader

Abstract

On one hand, the present invention discloses an antigenic epitope polypeptide of a breast cancer marker PMEPA1. The present invention also discloses a monoclonal antibody that can specifically bind to the PMEPA1 antigenic epitope polypeptide. The present invention also discloses a kit for breast cancer detection. The present invention designs two antigenic epitope polypeptides separated from each other based on screening sequences with good antigenicity and multiple antigenic epitopes, and then screens suitable monoclonal antibodies on this basis for the detection of PMEPA1 protein; the method has the following advantages: 1) the success rate of screening monoclonal antibodies can be improved; 2) the pairing test of monoclonal antibodies can be omitted; 3) the specificity of monoclonal antibodies can be improved. The kit of the present invention has good specificity and sensitivity, and is suitable for the detection of PMEPA1 protein.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and in particular relates to a monoclonal antibody and a kit thereof for detecting breast cancer. Background Art

[0002] Breast cancer is a phenomenon in which mammary epithelial cells proliferate uncontrollably under the influence of multiple carcinogenic factors. In the early stages of the disease, symptoms include breast lumps, nipple discharge, and enlarged axillary lymph nodes. In the late stages, cancer cells may metastasize to distant sites, leading to multi-organ lesions and directly threatening the patient's life.

[0003] Recent studies have shown that the occurrence and development of breast cancer is closely related to abnormal protein expression and abnormal activation of signal pathways. Studies have found that the prostate transmembrane protein, androgeninduced 1 (PMEPA1) gene in breast cancer cells is overexpressed 5 to 10 times compared with normal cells. It has been confirmed that PMEPA1 can have an important impact on the proliferation, invasion, metastasis and other biological behaviors of malignant tumor cells by participating in the regulation of multiple signal pathways, and plays a certain role in predicting the prognosis of patients with malignant tumors. Summary of the invention

[0004] In order to make up for the deficiencies of the prior art, one of the purposes of the present invention is to provide an antigenic epitope sequence of a breast cancer marker PMEPA1; a second purpose of the present invention is to provide a monoclonal antibody against the PMEPA1 antigenic epitope sequence.

[0005] Therefore, the present invention discloses an antigen epitope polypeptide of the breast cancer marker PMEPA1, wherein the amino acid sequence of the PMEPA1 antigen epitope polypeptide is:

[0006] Antigenic epitope peptide 1:LMGVNSTAAAAAGQPNVSCTCNCKRSLFQSM.

[0007] On the other hand, the present invention also discloses a monoclonal antibody that can specifically bind to the PMEPA1 antigen epitope polypeptide, the nucleotide sequence encoding the heavy chain variable region of the monoclonal antibody 1 that specifically binds to the antigen epitope polypeptide 1 is shown as SEQ ID NO.1, and the nucleotide sequence encoding the light chain variable region of the monoclonal antibody 1 that specifically binds to the antigen epitope polypeptide 1 is shown as SEQ ID NO.2.

[0008] Preferably, the heavy chain variable region sequence of the monoclonal antibody 1 of the present invention comprises CDR-H1, CDR-H2 and CDR-H3, and the sequences of CDR-H1, CDR-H2 and CDR-H3 of the heavy chain variable region are respectively:

[0009] CDR-H1:NSMN;

[0010] CDR-H2: EIRLKSNNYVTHYAESVKG;

[0011] CDR-H3: IYSPFAY;

[0012] The light chain variable region sequence of the monoclonal antibody 1 comprises CDR-L1, CDR-L2 and CDR-L3, and the sequences of CDR-L1, CDR-L2 and CDR-L3 of the light chain variable region are respectively:

[0013] CDR-L1:PPSSEKASIDVSTIVS;

[0014] CDR-L2: SATYRYI;

[0015] CDR-L3:QQHYSSPST.

[0016] Preferably, the heavy chain variable region sequence of the monoclonal antibody 1 of the present invention further comprises FR-H1, FR-H2, FR-H3 and FR-H4, and the sequences of FR-H1, FR-H2, FR-H3 and FR-H4 in the heavy chain variable region are:

[0017] FR-H1: ESGGGLVGSQPGGSMKLSCVASGFTIS;

[0018] FR-H2: WVRQSPEKGLDWVA;

[0019] FR-H3:RFTISRDDSKNSVYLQSMNNLRPEGSGIYYCTP;

[0020] FR-H4: WGQGTLVTVSA;

[0021] The light chain variable region sequence of the monoclonal antibody 1 further comprises FR-L1, FR-L2, FR-L3 and FR-L4, and the sequences of FR-L1, FR-L2, FR-L3 and FR-L4 of the light chain variable region are respectively:

[0022] FR-L1: DIVMSQSHKFDSTSVGDRVSITC;

[0023] FR-L2: WYQQKPGQSPKLLHY;

[0024] FR-L3:GVPDRFTASGSGTWFTFTISSVQAEDLAVYYC;

[0025] FR-L4: FGAGTCPTKLEL.

[0026] In another aspect, the present invention also discloses a use of the PMEPA1 antigen epitope polypeptide in preparing a breast cancer diagnostic reagent.

[0027] The present invention designs two antigenic epitope polypeptides separated from each other based on screening sequences with good antigenicity and multiple antigenic epitopes (as described in Example 1), and then screens suitable monoclonal antibodies for the detection of PMEPA1 protein. The method has the following advantages: 1) the success rate of screening monoclonal antibodies can be improved (avoiding the use of invalid antibodies during whole protein screening); 2) the pairing test of monoclonal antibodies can be omitted; 3) the specificity of monoclonal antibodies can be improved (antigenic epitopes are highly specific antigenic sites that can be specifically bound by multiple monoclonal antibodies).

[0028] Based on the screened monoclonal antibodies, a kit for detecting PMEPA1 protein is formed, which has good specificity and sensitivity and is suitable for detecting PMEPA1 protein. Although the detection method adopted by the present invention is a conventional ELISA method, the monoclonal antibodies screened by the present invention can also be applied to the detection of other immunological methods, such as colloidal gold detection, chemiluminescence detection, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 The prediction analysis results of the transmembrane region of PMEPA1 protein. Inside represents the intracellular region. The larger the inside value, the more likely it is that the amino acid is located in the intracellular region; Outside represents the extracellular region. The larger the outside value, the more likely it is that the amino acid is located in the extracellular region; Transmembrane represents the transmembrane region. The larger the Transmembrane value, the more likely it is that the amino acid is in the transmembrane region.

[0030] Figure 2 Results of secondary structure prediction and analysis of PMEPA1 protein. DETAILED DESCRIPTION

[0031] The present invention is further described below with reference to specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0032] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0033] Example 1: Design and synthesis of PMEPA1 antigen epitope polypeptide

[0034] PMEPA1 was searched from NCBI and the PMEPA1 sequences published in recent years were found. One of them (NM_020182.5) was selected as the target protein of this study. The transmembrane region ( Figure 1 ) and secondary structure ( Figure 2 ) were used for prediction analysis, and two of them were selected as PMEPA1 antigen epitope peptides, and the company was handed over to synthesize peptides for subsequent experiments. The design of the antigen epitope follows the following principles (see Chinese invention patent 2015106122558): select the surface area or internal area of ​​the cell membrane protein, avoid the transmembrane area; select sequences that do not form a-helix; the peptides at both ends are arranged more reasonably than those in the middle; avoid repetition within the protein; avoid peptides with strong homology.

[0035] After design, the two epitope peptide sequences are:

[0036] Epitope peptide 1: LMGVNSTAAAAAGQPNVSCTCNCKRSLFQSM;

[0037] Antigen epitope peptide 2: LGGPCPPSSNSGISATCYGSGGRMEGPPPTYS.

[0038] Example 2: Preparation of monoclonal antibodies against PMEPA1 antigen epitope polypeptides

[0039] 2.1 Animal Immunization The antigen epitope polypeptides prepared in Example 1 were used as antigens, fully emulsified with an equal mass of Freund's complete adjuvant, and then injected subcutaneously at multiple points in the dorsal abdomen of 8-week-old BALB / c female mice, 0.2 ml / mouse. After an interval of 2 weeks, an equal amount of antigen and an equal mass of Freund's incomplete adjuvant were taken for the first immunization, fully emulsified, and then injected intraperitoneally for the second time, 0.2 ml / mouse. After 2 weeks, double the dose of antigen was used for intraperitoneal immunization, and spleen cells were taken for cell fusion 3 days later.

[0040] 2.2 Cell fusion and hybridoma cell screening The spleen of mice was collected, ground and isolated, and then fused with myeloma Sp2 / 0 cell line using PEG method. The fused cells were resuspended in HAT medium and evenly plated in 96-well plates, with 100 μl per well, at 37°C and 5% CO 2Culture. After 5 days of culture in the cell culture incubator, replace the medium once with HAT medium, and replace the medium with HT medium on the 10th day, and wait until the fused cells cover 10-30% of the bottom of the well. Take the culture supernatant and detect the positive clones using the conventional indirect ELISA method coated with PMEPA1 antigen epitope polypeptide. A total of 98 positive wells were obtained, and 3 cell wells with strong positive reactions were selected. Three limiting dilution cell clonings were performed, and 1 hybridoma cell line was obtained, named No. 1 (obtained by screening after immunization with antigen epitope polypeptide 1) and No. 2 (obtained by screening after immunization with antigen epitope polypeptide 2). After passaging and multiple freezing and thawing, the cell lines can grow well and stably secrete antibodies. After expanded culture, they are used for ascites preparation and liquid nitrogen storage.

[0041] 2.3 Preparation and purification of ascites of monoclonal antibodies 8-week-old BALB / c female mice were intraperitoneally injected with pristane (0.3-0.5 ml / mouse). Seven days later, each mouse was injected with 1×10 hybridoma cells. 6 7 to 10 days after injection, the abdomen of the mouse was obviously swollen. The injection needle was used to take the ascites, centrifuged at 4℃8000rpm for 3min, and the supernatant was collected, which was the monoclonal antibody ascites. Take 1 volume of ascites, add 2 volumes of acetate buffer (0.06mol / L, pH 4.8), mix well, add caprylic acid (30μl / ml ascites) while stirring at room temperature, clarify at 4℃ for 2h, centrifuge at 4℃12000rpm for 20min, and collect the supernatant. Then use 50% saturated ammonium sulfate to precipitate the immunoglobulin, let it stand at 4℃ for 2 hours, centrifuge at 4℃3000rpm for 30min, and collect the precipitate. Dissolve the precipitate with 2 volumes of PBS and dialyze it with PBS overnight to obtain the purified ascites antibody, which is stored at -70℃ for later use.

[0042] 2.4 Monoclonal Antibody Analysis The total RNA of the hybridoma cells was extracted and reverse transcribed, and the obtained cDNA was stored below -15°C for later use. Specific nested PCR primers were designed, and the target gene was amplified by conventional PCR method. Among them, the design of the primer sequence was carried out according to the literature (CN 111393525 B). After sequencing, the amino acid sequence information of the variable region of monoclonal antibody 1 (prepared after immunization with antigen epitope polypeptide 1) is shown in Table 1; the nucleotide sequence encoding the heavy chain variable region of monoclonal antibody 1 is shown in SEQ ID NO.1, and the nucleotide sequence encoding the light chain variable region of monoclonal antibody 1 is shown in SEQ ID NO.2.

[0043] Table 1 Monoclonal antibody amino acid sequence information

[0044]

[0045] Example 3: Establishment of an immunological method for detecting PMEPA1 and preparation of a kit thereof

[0046] 3.1 Preparation of the kit The preparation method of the conventional ELISA kit is briefly described as follows:

[0047] 3.1.1 Preparation of ELISA plate: Use monoclonal antibody 1 to coat the ELISA plate (coating solution is 0.05M carbonate buffer, pH 9.6), 100 ng / well, 0.1 ml / well, coat overnight at 4°C, wash 3 times, block with PBST containing 1% BSA, incubate at 37°C for 2h, wash and store at -15°C for later use;

[0048] 3.1.2 Kit detection method: Use sample diluent (PBST buffer containing 1% BSA) to dilute the sample to be tested 50 times, mix well and add to the coated ELISA plate, 0.1 ml / well, incubate at 37°C for 1h; after washing, add HRP-labeled monoclonal antibody 2 (HRP labeling is a conventional modified sodium periodate method) diluted 1:10000 with sample diluent, 0.1 ml / well, incubate at 37°C for 30min; after washing, add 0.1 ml TMB single-component colorimetric solution, incubate at 37°C for 10min; add stop solution (2M sulfuric acid), measure OD450nm value, and judge it as positive when P / N value is greater than 2.1, otherwise it is negative, where P is the OD450nm value of the sample and N is the OD450nm value of the blank control.

[0049] 3.2 Kit detection In this study, blood samples from 80 breast cancer patients and 80 non-patients were obtained from a hospital in Guangdong Province. The PMEPA1 protein was detected using the kit established in 3.1. The results showed that all 80 breast cancer patients detected by the kit were positive, while all 80 non-patients were negative, indicating that the kit has good specificity and sensitivity.

[0050] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. An antigen epitope polypeptide of a breast cancer marker PMEPA1, characterized in that: The amino acid sequence of the PMEPA1 antigen epitope polypeptide is: Antigenic epitope peptide 1:LMGVNSTAAAAAGQPNVSCTCNCKRSLFQSM.

2. A monoclonal antibody that can specifically bind to the PMEPA1 antigen epitope polypeptide according to claim 1, characterized in that: The nucleotide sequence encoding the heavy chain variable region of the monoclonal antibody 1 that specifically binds to the antigen epitope polypeptide 1 is shown in SEQ ID NO.1, and the nucleotide sequence encoding the light chain variable region of the monoclonal antibody 1 that specifically binds to the antigen epitope polypeptide 1 is shown in SEQ ID NO.

2.

3. The monoclonal antibody according to claim 2, characterized in that The heavy chain variable region sequence of the monoclonal antibody 1 comprises CDR-H1, CDR-H2 and CDR-H3, and the sequences of CDR-H1, CDR-H2 and CDR-H3 of the heavy chain variable region are respectively: CDR-H1:NSMN; CDR-H2: EIRLKSNNYVTHYAESVKG; CDR-H3: IYSPFAY; The light chain variable region sequence of the monoclonal antibody 1 comprises CDR-L1, CDR-L2 and CDR-L3, and the sequences of CDR-L1, CDR-L2 and CDR-L3 of the light chain variable region are respectively: CDR-L1:PPSSEKASIDVSTIVS; CDR-L2: SATYRYI; CDR-L3:QQHYSSPST.

4. The monoclonal antibody according to claim 2, characterized in that The heavy chain variable region sequence of the monoclonal antibody 1 further comprises FR-H1, FR-H2, FR-H3 and FR-H4, and the sequences of FR-H1, FR-H2, FR-H3 and FR-H4 in the heavy chain variable region are respectively: FR-H1: ESGGGLVGSQPGGSMKLSCVASGFTIS; FR-H2: WVRQSPEKGLDWVA; FR-H3:RFTISRDDSKNSVYLQSMNNLRPEGSGIYYCTP; FR-H4: WGQGTLVTVSA; The light chain variable region sequence of the monoclonal antibody 1 further comprises FR-L1, FR-L2, FR-L3 and FR-L4, and the sequences of FR-L1, FR-L2, FR-L3 and FR-L4 of the light chain variable region are respectively: FR-L1: DIVMSQSHKFDSTSVGDRVSITC; FR-L2: WYQQKPGQSPKLLHY; FR-L3:GVPDRFTASGSGTWFTFTISSVQAEDLAVYYC; FR-L4: FGAGTCPTKLEL.

5. Use of the monoclonal antibody according to claim 2 in the preparation of a diagnostic reagent for breast cancer.